Cited by 1,070Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, Bissan, Banerji, Udai, Workman, Paul·2012·Nature Biotechnology

Open this paper in CoChat — free account

Abstract

Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.

Integrity signals

Registry

Crossref · 10.1038/nbt.2284

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574

Show all 172 references

Research works printed but not linked: 1

Goldie, J.H. & Coldman, A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 701–800 of 999

Unpicking the Combination Lock for Mutant BRAF and RAS Melanomas
Al‐Lazikani, B., & Workman, P. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0520 · Cited by 7
Self-citation
Identifying enriched drug fragments as possible candidates for metabolic engineering
Sharma, S., Karri, K., Thapa, I., Bastola, D. K., & Ghersi, D. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0205-6 · Cited by 7
“…of cancer biology, with some notable exceptions the search for “sil-ver bullet” therapies has now largely been replaced by a quest for novel targets that can be simultaneously modulated by combinatorial therapies [1, 3], akin to what has been accomplished for the treatment of HIV infections [4].”
Background
Molecular and Clinical Oncology
Vahedi, A., Fazeli, S. A., Hashemi, S. M., Arabpour-Dahouei, F., Davarian, A., & Golabchifard, R. (2015) · Cited by 8
Carbon-based nanoparticles and dendrimers for delivery of combination drugs
Ranch, K. M., Shukla, M. R., Maulvi, F. A., & Desai, D. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820779-6.00009-8 · Cited by 7
In Silico Modeling and Quantification of Synergistic Effects of Multi-Combination Compounds: Case Study of the Attenuation of Joint Pain Using a Combination of Phytonutrients
Ayyadurai, V. A. S., & Deonikar, P. (2022) · Applied Sciences · doi:10.3390/app121910013 · Cited by 7
Assessment of Drug Susceptibility for Patient-Derived Tumor Models through Lactate Biosensing and Machine Learning
Zhang, J., Hong, Z., Lu, W. J., Fang, T., Ren, Y., Yin, S., Xuan, Q., Li, D., Xi, J., & Yao, B. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02381 · Cited by 7
Implantable microdevices for treating brain tumors
Yearley, A. G., Patel, R. V., Blitz, S. E., Park, S., Madinger, A. M., Li, J., Johnston, B. R., Peruzzi, P. P., Lee, S., Srinivasan, S. S., et al. (2023) · Device · doi:10.1016/j.device.2023.100068 · Cited by 7
Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2−, triple positive and triple-negative breast cancer patients
Pacheco-Velázquez, S. C., Gallardo‐Pérez, J. C., Aguilar-Ponce, J. L., Villarreal, P., Ruiz-Godoy, L. M., Pérez-Sánchez, M., Marín‐Hernández, Á., Ruíz‐García, E., Meneses-García, A., Moreno‐Sánchez, R., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2676 · Cited by 7
Utilising established SDL-screening methods as a tool for the functional genomic characterisation of model and non-model organisms
Usher, J., Thomas, G. H., & Haynes, K. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov091 · Cited by 6
Nanoscale polyelectrolyte complexes encapsulating mRNA and long-chained siRNA for combinatorial cancer gene therapy
Kim, M. G., Jo, S. D., Jeong, J. H., & Kim, S. H. (2018) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2018.04.005 · Cited by 7
Thiol redox-sensitive Cationic Polymers for Dual Delivery of Drug and Gene
Syamala, P. S., & Rekha, M. R. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0041 · Cited by 7
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines
Close, D. A., Kirkwood, J. M., Fecek, R. J., Storkus, W. J., & Johnston, P. A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220970917 · Cited by 7
Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies
Wild, S. A., Cannell, I. G., Kania, K., Nicholls, A., Bressan, D., CRUK IMAXT Grand Challenge Team, Hannon, G. J., & Sawicka, K. (2022) · eLife · doi:10.7554/elife.80981 · Cited by 7
Cancer’s Darwinian dilemma: an evolutionary tale in three acts
Greaves, M. F. (2015) · BMJ · doi:10.1136/bmj.h6581 · Cited by 7
First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations
Yoon, S., & Kim, H. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098389 · Cited by 6
“However, a small proportion of tumors are composed of multidrug-resistance (MDR) cancer cells, which include cancer stem cells (CSCs) [1,2].”
Background
DCGG: drug combination prediction using GNN and GAE
Ziaee, S. S., Rahmani, H., Tabatabaei, M., Vlot, A. H. C., & Bender, A. (2024) · Progress in Artificial Intelligence · doi:10.1007/s13748-024-00314-3 · Cited by 6
“…range of drugs with different indications in contrast to previous approaches that limited their work on speciﬁc tasks like treating cancers [6, 10, 14–16 , 22– 27 In the following sections, we ﬁrst deep dive into the state-of-the-artmodelsintheliteratureinDrug–DrugCombination prediction in Sect.”
Prioritizing drug targets by perturbing biological network response functions
Perrone, M. C., Lerner, M. G., Dunworth, M., Ewald, A. J., & Bader, J. S. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012195 · Cited by 7
“While the focus of this initial description of N ET P ERT has been on single-vertex perturbations, drug combinations are often used in cancer therapy and drug repositioning [95–98].”
Background
Antimigratory Effect of Lipophilic Cations Derived from Gallic and Gentisic Acid and Synergistic Effect with 5-Fluorouracil on Metastatic Colorectal Cancer Cells: A New Synthesis Route
Suárez-Rozas, C., Jara, J. A., Cortés, G., Rojas, D., Araya-Valdés, G., Molina‐Berríos, A., González‐Herrera, F., Fuentes-Retamal, S., Aránguiz, P., Campodónico, P. R., et al. (2024) · Cancers · doi:10.3390/cancers16172980 · Cited by 6
Synthesis, structural characterization, QSAR and docking studies of a new binuclear nickel (II) complex based on the flexible tetradentate N-donor ligand as a potent antibacterial and anticancer agent
Beheshti, A., Hashemi, F., Behavndi, F., Zahedi, M., Kolahi, M., Motamedi, H., & Mayer, P. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.06.098 · Cited by 6
Identification of cisplatin sensitizers through high-throughput combinatorial screening
Sun, Y.-C., Jiang, W., Lu, W., Song, M., Liu, K., Chen, P., Chang, A. E. B., Ling, J., Chiao, P. J., Hu, Y., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4447 · Cited by 6
“These drug combinations are largely the results of empirical clinical trials rather than mechanism-based design, as mechanistic studies and clinical evaluation require vast resources (15).”
Toxicity of Combinations of Kinase Pathway Inhibitors to Normal Human Cells in a Three-Dimensional Culture
Nejad, P. R., Thakuri, P. S., Singh, S. K., Lamichhane, A., Heiss, J., & Tavana, H. (2021) · SLAS TECHNOLOGY · doi:10.1177/24726303211008858 · Cited by 6
“26(3) 255 –264 © Society for Laboratory Automation and Screening 2021 DOI: 10 1177/24726303211008 58 journals.”
Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents
Djurian, A., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060460 · Cited by 6
“In the pharmaceutical industry, cancer therapeutics have a long history in the transformation of treatment options, including chemotherapy [14,15], targeted therapy [16], biologics [17], and combination therapy [18].”
Background
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Kebir, S., Ullrich, V., Berger, P., Dobersalske, C., Langer, S., Rauschenbach, L., Trageser, D., Till, A., Lorbeer, F. K., Wieland, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0611 · Cited by 7
“Combinatorial drug therapy is widely considered a mainstay of treatment in malignant cancers (57), and heterogeneity of driving disease mechanisms and associated targets may serve as a wellgrounded basis for the choice of treatment combinations (58).”
Background
Performance evaluation of drug synergy datasets using computational intelligence approaches
Rani, P., Dutta, K., & Kumar, V. (2023) · Multimedia Tools and Applications · doi:10.1007/s11042-023-15723-0 · Cited by 6
Preparation and characterization of alginate gel core-lipid nanocapsules for co-delivery of hydrophilic and hydrophobic anti-cancer drugs
Poudel, B. K., Pradhan, R., Gupta, B., Choi, J. Y., Yong, C. S., & Kim, J. O. (2014) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-014-0152-1 · Cited by 6
Application of Theranostics to Measure and Treat Cell Heterogeneity in Cancer
Lelièvre, S. A., Hodges, K. B., & Vidi, P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00026-8 · Cited by 8
Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism
Ruhnau, J., Parczyk, J., Danker, K., Eickholt, B. J., & Klein, A. (2020) · BMC Cancer · doi:10.1186/s12885-020-07062-2 · Cited by 7
“Synergistic effects are desirable, but additive effects or in some cases even compounds with slight antagonisms might be useful as well [18, 59].”
Introduction to polysaccharides
Nguyen, T. T. H., Qureshi, D., Lim, S., Jin, J., Mok, I.-K., Pal, K., & Kim, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819239-9.00002-6 · Cited by 6
Model‐Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers
Kirouac, D., Lahdenranta, J., Du, J., Yarar, D., Onsum, M., Nielsen, U., & McDonagh, C. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.19 · Cited by 5
“thus requires approaches to rationally combine therapies and select patients most likely to respond to such combinations.(4) Quantitative models relating the molecular features of tumors to pharmacologic response patterns are thus essential for achieving the vision of precision medicine.”
Background
Interaction-aware adaptive network for drug-drug interaction prediction
Niu, D., Wang, X., Deng, Z., Tang, B., & Li, Z. (2026) · Pattern Recognition · doi:10.1016/j.patcog.2026.113172 · Cited by 5
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma
Garcha, H. K., Nawar, N., Sorger, H., Erdogan, F., Aung, M. M. K., Sedighi, A., Manaswiyoungkul, P., Seo, H., Schönefeldt, S., Pölöske, D., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111321 · Cited by 5
“Furthermore, combination treatments have allowed alleviation of drug-induced toxicity and adverse effects, by enabling administration of each drug at lower doses [32,34].”
Background
Attenuation of Aging-Related Oxidative Stress Pathways by Phytonutrients: A Computational Systems Biology Analysis
Ayyadurai, V. A. S., & Deonikar, P. (2023) · Nutrients · doi:10.3390/nu15173762 · Cited by 5
Folate-receptor-targeted co-self-assembly carrier-free gemcitabine nanoparticles loading indocyanine green for chemo-photothermal therapy
Kuang, S., Liu, S., Wang, S., Yang, L., Zeng, Y., & Ming, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1266652 · Cited by 5
“As an alternative approach, the co-delivery of multifunctional nanoagents is promising for overcoming these problems and enhancing anticancer drug efficacy (Al-Lazikani et al., 2012; Meng et al., 2015; Li et al., 2022).”
Background
SNSynergy: Similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations
Huangfu, X., Zhang, C., Li, H., Li, S., & Li, Y. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108054 · Cited by 5
Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data
Chen, J., Han, H., Li, L., Chen, Z., Liu, X., Li, T., Wang, X., Wang, Q., Zhang, R., Feng, D., et al. (2025) · PeerJ · doi:10.7717/peerj.19078 · Cited by 5
Discovery of dual CDK4/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivo
Zhang, Y., Luo, Z., Jiang, Y., Zheng, L. T., Ma, L., Zheng, Y., Zou, M., Kong, L., & Wang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117495 · Cited by 5
A Perspective Analysis: Companion Diagnostics: An Evolving Paradigm in 21st Century Healthcare
Kaufmann, M., Keppens, M., & Blair, E. D. (2015) · Personalized Medicine · doi:10.2217/pme.15.2 · Cited by 5
Prediction model for synergistic anti-tumor multi-compound combinations from traditional Chinese medicine based on extreme gradient boosting, targets and gene expression data
Sun, M., She, S., Chen, H., Cheng, J., Ji, W., Wang, D., & Feng, C. (2022) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720022500160 · Cited by 5
Fine tuning a logical model of cancer cells to predict drug synergies: combining manual curation and automated parameterization
Flobak, Å., Zobolas, J., Vázquez, M., Steigedal, T. S., Thommesen, L., Grislingås, A., Niederdorfer, B., Folkesson, E., & Kuiper, M. T. R. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1252961 · Cited by 7
Exploiting Cancer Dependence on Molecular Chaperones
Sharp, S. Y., Jones, K., & Workman, P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00009-7 · Cited by 5
Self-citation
Minimizing Bias in Target Selection by Exploiting Multidisciplinary Big Data and the Protein Interactome
Al‐Lazikani, B., & Workman, P. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0133 · Cited by 5
Self-citation
In-Silico Analysis & In-Vivo Results Concur on Glutathione Depletion in Glyphosate Resistant GMO Soy, Advancing a Systems Biology Framework for Safety Assessment of GMOs
Ayyadurai, V. A. S., Hansen, M., Fagan, J., & Deonikar, P. (2016) · American Journal of Plant Sciences · doi:10.4236/ajps.2016.712149 · Cited by 5
“In oncology, CytoSolve’s unique capability for in silico modeling to derive multi-combination therapeutics has been independently recognized by leading cancer researchers [12].”
Background
Pattern Discovery from High-Order Drug-Drug Interaction Relations
Chiang, W.-H., Schleyer, T., Shen, L., Li, L., & Ning, X. (2018) · Journal of Healthcare Informatics Research · doi:10.1007/s41666-018-0020-2 · Cited by 5
“A very related research area is on combinatorial drug therapy against cancer and infection [2], in which numerical models are built to predict dose responses to multiple drugs [31, 42] in order to quantify efficacy of multiple drugs admitted together for disease treatment.”
Background
Response envelope analysis for quantitative evaluation of drug combinations
Du, D., Chang, C.-H., Wang, Y., Tong, P., Chan, W., Chiu, Y., Peng, B., Tan, L., Weinstein, J. N., & Lorenzi, P. L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz091 · Cited by 5
A Factorization Machine Based Deep Neural Network for Synergism of Cancer Drug Combinations Prediction
Ma, X., Lin, W., Wu, X., Xie, H., Chen, Y., Dong, S., & Cao, X. (2021) · International Conference on Pattern Recognition and Artificial Intelligence (PRAI) · doi:10.1109/prai53619.2021.9551036 · Cited by 5
MMP9-Sensitive PEG-Shedding Nanoliposomes for Targeted Codelivery of Erlotinib and Doxorubicin to MDA-MB-231 Cells
Kim, S. Y., Yoon, J., Lee, H.-S., Cho, C., & Seong, H. (2021) · ACS Applied Polymer Materials · doi:10.1021/acsapm.1c01228 · Cited by 5
Reciprocal Regulation of Hippo and WBP2 Signalling—Implications in Cancer Therapy
Lim, Y. X., Lim, Y. X., Seah, S. H., & Lim, Y. P. (2021) · Cells · doi:10.3390/cells10113130 · Cited by 5
Omics approaches to individual variation: modeling networks and the virtual patient
Lehrach, H. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.3/hlehrach · Cited by 5
“Drug”
Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation
Ding, X., Krutzik, P. O., Ghaffari, A. A., Zhaozhi, Y., Miranda, D., Cheng, G., Ho, C., Nolan, G. P., & Sanchez, D. J. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104598 · Cited by 5
“The use of drug combinations is well documented in both cancer and infectious disease therapy (Al-Lazikani et al., 2012; Arts and Hazuda, 2012; George et al., 2015).”
Background
Combinatorial Inhibition of Cell Surface Receptors Using Dual Aptamer-Functionalized Nanoconstructs for Cancer Treatment
Lee, H., Kim, T. H., Park, D., Jang, M., Chung, J. J., Kim, S. H., Kim, S., Lee, K. H., Jung, Y., & Oh, S. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070689 · Cited by 5
“Because minimizing overlapping toxicity and drug resistance is critically important for their clinical success, specific target molecules at the appropriate concentrations should be used [1,4].”
Background
Nanomedicine—Nanoparticles in Cancer Imaging and Therapy
Hauser-Kawaguchi, A., & Luyt, L. G. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_10 · Cited by 5
An open-source screening platform accelerates discovery of drug combinations
Wright, W. C., Pan, M., Phelps, G. A., Low, J. A., Currier, D. G., Sanjali, A., Trotter, M., Hwang, J., Chapple, R. H., Liu, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66223-8 · Cited by 4
TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma
Amin, N. D., Wang, H., Song, Q., Bhaskar, M., Yadav, S. P., Gilbert, M. R., Pant, H. C., Tabouret, É., & Zhuang, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411733 · Cited by 4
“Improving the efficacy of irinotecan has the potential to enhance both the survival and quality of life of mCRC patients [23].”
Combining Bioactive Cell-Penetrating Peptides and Vemurafenib to Produce Peptide–Drug Conjugates with Activity Against Drug-Resistant Melanoma Cells
Palombi, I. R., White, A. M., Koda, Y., Craik, D. J., Henriques, S. T., Lawrence, N., & Malins, L. R. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02367 · Cited by 4
Systems Pharmacology: Enabling Multidimensional Therapeutics
Maudsley, S. R., Leysen, H., van Gastel, J., & Martin, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00017-7 · Cited by 5
Towards computational prediction of anti-cancer activity: Making connection between IC50 values and metal–ligand interaction energies in some NHC complexes of groups 10 and 11
Naderizadeh, B., Bayat, M., Ranjbaran, M., & Salehzadeh, S. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.117310 · Cited by 4
Understanding the role of Cripto-1 in cancer progression and therapeutic strategies
Zeng, Q., Gao, Y., & Zhou, Y. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03023-2 · Cited by 4
“Identifying the distinctive profile characterizing the subgroup of CSCs to seek antigens and biomarkers employed as appealing targets has been a key difficulty for most researchers over the last few decades [55].”
Background
Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas
Dougherty, J. M., Harvey, K., Liou, A., Labella, K., Moran, D. H., Brosius, S. N., & Raedt, T. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0277305 · Cited by 5
Hybrid peptides as platform for synchronized combination therapy
Ashrafichoobdar, E., Perez, T., Ayalew, L., Gorbanwand, V., Monroy, J., & Slowinska, K. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113326 · Cited by 4
High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line
Wang, S., Oliveira-Silveira, J., Fang, G., & Kang, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12057-4 · Cited by 4
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening
Oikonomou, A., Watrin, T., Valsecchi, L., Scharov, K., Savino, A. M., Schliehe‐Diecks, J., Bardini, M., Fazio, G., Bresolin, S., Biondi, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34033 · Cited by 4
“On the other hand, it offers the opportunity of targeting diverse or inter-connected pathological pathways at the same time, avoiding the generation of resistant clones [3].”
Background
The adenoviral E4orf4 protein: A multifunctional protein serving as a guide for treating cancer, a multifactorial disease
Basis, A., Sharf, R., & Kleinberger, T. (2024) · Tumour Virus Research · doi:10.1016/j.tvr.2024.200303 · Cited by 4
“Combination therapies have the potential to target multiple pathways simultaneously, increasing treatment efficacy while potentially reducing side effects by allowing for lower doses of individual drugs [12,13].”
Functional genomics lead to new therapies in follicular lymphoma
Oricchio, E., & Wendel, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12120 · Cited by 4
Discovering Anti-platelet Drug Combinations with an Integrated Model of Activator-Inhibitor Relationships, Activator-Activator Synergies and Inhibitor-Inhibitor Synergies
Lombardi, F., Golla, K., Fitzpatrick, D. J., Casey, F., Moran, N. M., & Shields, D. C. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004119 · Cited by 4
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells
Al-Saffar, N. M. S., Agliano, A., Marshall, L. V., Jackson, L. E., Balarajah, G., Sidhu, J. K., Clarke, P. A., Jones, C., Workman, P., Pearson, A. D. J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180263 · Cited by 4
Self-citation
Novel Early Phase Clinical Trial Design in Oncology
O’Brien, C., Carter, L., Cook, N., & Dean, E. J. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0205-7 · Cited by 4
“Combination studies require robust preclinical data as their basis with evidence of synergy or additivity of the combination therapy as opposed to single-agent use of drugs, which is sometimes lacking [55].”
Background
Modelling approaches in tumor microenvironment.
Crespo, I., Coukos, G., Doucey, M., & Xénarios, I. (2018) · doi:10.35841/cancer-immunology.1.1.26-40 · Cited by 4
New Insights into Cancer Targeted Therapy: Nodal and Cripto-1 as Attractive Candidates
Arboretto, P., Cillo, M., & Leonardi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157838 · Cited by 4
“In the past few decades, the major challenge of most scientists has been to identify the unique profile that characterize the subpopulation of CSCs searching for antigens and biomarkers to be used as attractive targets [80].”
Background
A machine learning framework for predicting synergistic and antagonistic drug combinatorial efficacy
Mei, S. (2022) · Journal of Mathematical Chemistry · doi:10.1007/s10910-022-01331-0 · Cited by 5
“Synergistic polypharmacy is especially effective for the treatment of complex diseases like cancer [6].”
Background
Optimized scaling of translational factors in oncology: from xenografts to RECIST
Baaz, M., Cardilin, T., Lignet, F., & Jirstrand, M. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04458-8 · Cited by 5
“, synergistic effects between the drugs and slower onset of resistance [11, 12].”
Background
An Albumin-Holliday Junction Biomolecular Modular Design for Programmable Multifunctionality and Prolonged Circulation
Dinesen, A., Andersen, V. L., Elkhashab, M., Pilati, D., Bech, P., Fuchs, E., Samuelsen, T. R., Winther, A., Cai, Y., Märcher, A., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00491 · Cited by 5
Fluoroquinolones upregulate insulin-like growth factor–binding protein 3, inhibit cell growth and insulin-like growth factor signaling
Chung, C., & Chen, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176421 · Cited by 4
Roles of GST-π and polβ Genes in Chemoresistance of Esophageal Carcinoma Cells
Tang, Y., Xuan, X., Li, M., & Dong, Z. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7375 · Cited by 4
“Although recombinant lentivirus targeting the polβ gene induced successful downregulation of gene expression and decrease in RI, MDR of transplanted tumors was not significantly altered.”
BackgroundInfluential
Drug Screening Platforms and RPPA
Dawson, J. C., Warchal, S. J., & Carragher, N. O. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9755-5_11 · Cited by 4
Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
Bhattacharya, B., Low, S. H. H., Chong, M. L., Chia, D., Koh, K. X., Sapari, N. S., Kaye, S. B., Hung, H., Benoukraf, T., & Soong, R. (2016) · Oncotarget · doi:10.18632/oncotarget.8692 · Cited by 4
“Combination therapy, entailing treatment using two or more agents together, has become a common strategy for optimizing treatment efficacy, and reducing toxicity and drug resistance [1].”
Background
Targeted sequencing reveals genetic variants associated with sensitivity of 79 human cancer xenografts to anticancer drugs
Udagawa, C., Sasaki, Y., Suemizu, H., Ohnishi, Y., Ohnishi, H., Tokino, T., & Zembutsu, H. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5533 · Cited by 4
Drug Combination Antagonism and Single Agent Dominance Result from Differences in Death Activation KineticsPreprint
Richards, R., Schwartz, H. R., Stewart, M. S., Cruz‐Gordillo, P., Honeywell, M. E., Joyce, A. J., Landry, B. D., & Lee, M. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/805093 · Cited by 4
“!" ! = !"! + !"! − !"! ∗ (1 − !!!! !!!! ) (1) where LF0 is the lethal fraction at time 0, LFp is the plateau, DO is the onset time of death, and DR is maximum rate of death.”
Background
Personalized anti-cancer drug combination prediction by an Integrated Multi-level NetworkPreprint
Feng, F., Zhang, Z., Ding, G., Hui, L., Li, Y., & Li, H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.12.092239 · Cited by 4
“Therefore, 44 combining anti-cancer medicines has become a feasible alternative because of their advantages 45 on sensitizing cancer response, modulating multiple biological progresses or pathways and 46 reducing side effects[2].”
Background
Molecular Compatibility in Chinese Medicine for Cancer Treatment and Drug Development: From Traditional Wisdom to Innovative Therapeutics
Zhang, R., You, Y., Gao, Q., Sun, X., Zheng, C., & Xie, T. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-4152-y · Cited by 3
Exploring the Co-delivery of Sorafenib and Venetoclax to Induce Ferroptosis and Apoptosis Mediated Cancer Cell Death using Surface Modified PLGA Nanoparticles
Patel, D., Bhardwaj, S., Yadav, V., Kuche, K., Dhake, P., & Jain, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03304-3 · Cited by 3
“Combinatorial chemotherapy relies on the rationale of co-administering chemotherapeutic agents with non-overlapping molecular mechanisms, thereby fortifying tumor cell eradication and notably curbing the development of resistance [4].”
Molecular Insights into the Interaction Between Metformin and Caffeine: The Time-Dependent Antagonism and Modulation of p53 Signaling in Cancer Cells
Zeljković, V., Bogavac, M. A., Dekić, M., Minić, S., Mahmutović, E., Kunkin, V., Marković, Z., & Karaman, M. (2026) · Molecules · doi:10.3390/molecules31111877 · Cited by 4
“Targeting both metabolic and stress response pathways may provide a synergistic framework for enhancing anticancer efficacy [19].”
The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks
Saha, S., Ghosh, M., & Dutta, S. K. (2017) · RSC Advances · doi:10.1039/c7ra08625c · Cited by 3
Role of Artificial Intelligence in Drug Discovery to Revolutionize the Pharmaceutical Industry: Resources, Methods and Applications
Singh, P. K., Sachan, K., Khandelwal, V., Singh, S., & Singh, S. (2024) · Recent Patents on Biotechnology · doi:10.2174/0118722083297406240313090140 · Cited by 3
Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations
Ghosh, A., & Fortino, V. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.12.003 · Cited by 4
Predicting Synergistic Drug Combinations Based on Fusion of Cell and Drug Molecular Structures
Yan, S., Yu, G., Yang, J., & Chen, L. (2025) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-025-00695-6 · Cited by 3
“In addition, combination therapy offers the additional benefit of lowering the dosage and minimizing the side effects of each individual drug [2], especially in cancers that are more resistant to drugs, and combination therapy has been recognized as an effective method for many years [3–5].”
Design, Synthesis, and Biological Evaluation of Naphthoquinone Salts as Anticancer Agents
Cheng, Y., Yu, T. T., Olzomer, E. M., Hoehn, K. L., Byrne, F. L., Kumar, N., & Black, D. S. (2025) · Molecules · doi:10.3390/molecules30091938 · Cited by 3
“…and selectivity are less likely to lead to resistance, as they create a more intense selective pressure on cancer-speci ﬁ c pathways Such agents are also more amenable to combination therapies with immunotherapies, targeted agents, or radiotherapy, without exacerbating body toxicity [27,28].”
Cyclodextrins as non-viral vectors in cancer theranostics: A review
Qu, G., Xu, H., Ma, L., Feng, S., Li, Y., & Zhang, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143697 · Cited by 7
Precision oncology informatics for anticancer drug combination responses: A systematic review
Rahaman, S., Wang, P., Yu, J., Rahman, T., Toseef, M., Sayem, I. M., Li, X., & Wong, K. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110788 · Cited by 3
Mechanistically Explainable AI Model for Predicting Synergistic Cancer Therapy Combinations
Si, H., Kumar, S., Lata, S., Ahmad, A., Ghosh, S. K., Stephansen, K., Nagarkar, D. R., Zhou, E., & Higgs, B. W. (2025) · Current Oncology · doi:10.3390/curroncol32100548 · Cited by 3
Combination therapy
Iqubal, M. K., Saleem, S., Chaudhuri, A., Iqubal, A., Narang, J. K., Ali, J., & Baboota, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820779-6.00010-4 · Cited by 3
Functional Nanofiber for Drug Delivery Applications
Imani, R., Yousefzadeh, M., & Nour, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-53655-2_34 · Cited by 3
Molecular targets in cancer therapy
Kummar, S., & Doroshow, J. H. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.170 · Cited by 3
Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation
Cockrell, C., & Axelrod, D. E. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0271 · Cited by 3
“Another strategy to overcome the resistance of cancer cells to a single drug, or resistance to each of the two drugs separately, is to treat cancer cells with a combination of two drugs with different mechanisms of action (29, 30, 59).”
Background
The n-Butanol Extract Obtained from the Inner Bark of Tabebuia rosea (Bertol.) DC, Specioside, and Catalposide Induce Leukemia Cell Apoptosis in the Presence of Apicidin
Pepinosa, N. Y. G., Veloza, L. A., & Arias, J. C. (2024) · Molecules · doi:10.3390/molecules29173986 · Cited by 3
Parameter, noise, and tree topology effects in tumor phylogeny inference
Tomlinson, K., & Oesper, L. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0626-0 · Cited by 3
“Treatment strategies that take the evolutionary history of a tumor into account by specifically targeting clonal mutations (those present in every tumor cell) [12] or that combine drugs based on a patient’s specific tumor evolutionary history [13] have the potential to be more effective.”
Background
A Time Travel Journey Through Cancer Therapies
Cravo, A. S., & Mrsny, R. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_1 · Cited by 3
Hollow Micro-/Nano-Particles from Biopolymers: Fabrication and Applications
Qian, J. (2014) · ACS symposium series · doi:10.1021/bk-2014-1175.ch014 · Cited by 3
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
Lüpfert, C., Dyroff, M. C., von Richter, O., Gallemann, D., Bawab, S. E., Dolgos, H., Jung, D. T., Hecht, S., & Johne, A. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12360 · Cited by 3
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clonesPreprint
Ianevski, A., Nader, K. M., Bulanova, D. R., Giri, A. K., Ruokoranta, T. M., Kuusanmäki, H. A., Ikonen, N., Sergeev, P., Vähä-Koskela, M. J. V., Vähärautio, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.26.546571 · Cited by 3
A highly annotated drug combination resource for catalyzing precision combinatorial therapy
You, T., Wang, L., Wang, J., Xu, D., Xu, X., Li, N., Li, M. J., Wang, H., & Dong, X. (2025) · Scientific Data · doi:10.1038/s41597-025-05630-4 · Cited by 3

Authors: Al-Lazikani, B., Banerji, U., & Workman, P.
Affiliations: Royal Marsden NHS Foundation Trust (GB)
Institute of Cancer Research (GB)
Corresponding author: Banerji, Udai
Workman, Paul
ORCID: Banerji, Udai
Workman, Paul
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 30
Issue: 7
Pages: 679-692
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.2284
OpenAlex: W2061061337
Cited by: 1,070
References: 172
Citations by year: 2026: 63 · 2025: 80 · 2024: 71 · 2023: 73 · 2022: 87 · 2021: 73 · 2020: 80 · 2019: 91 · 2018: 81 · 2017: 76 · 2016: 83 · 2015: 90 · 2014: 69 · 2013: 46 · 2012: 6
FWCI: 5.04
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Funders: NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Cancer Research UK (C309/8992, 11566, C309/A8274)
National Institute for Health and Care Research
National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: combination therapy, targeted cancer therapy, driver mutations, synthetic lethality, tumor vulnerability, precision oncology, acquired drug resistance, de novo resistance, polygenic resistance, cytotoxic chemotherapy
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Combined Modality Therapy, Humans, Neoplasms, Drug Design, Genome, Human, Genetic Heterogeneity, Metabolic Networks and Pathways, Precision Medicine, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combinatorial drug therapy for cancer in the post-genomic era

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks